Inventor · disambiguated record
Andrew Kaiser
Also filed as: KAISER ANDREW · KAISER ANDREW DIDIER MATHEW
11 granted patents·13 pending applications·93 citations·filing 2002–2024
89Inventor score
Files withMILTENYI BIOTEC BV & CO KG15MILTENYI BIOTEC GMBH6MILTNEYI BIOTEC B V & CO KG1UMC UTRECHT HOLDING BV1
Top patents by PatentIndex Score
24 records- 0196US10131876B2Method for automated generation of genetically modified T cellsMILTENYI BIOTEC GMBH·Filed 2015·Granted Nov 20, 2018·49 cites·16 claims
- 0295US11419935B2Immunotherapy method comprising administering a combination of immune effector cells and non-target hematopoietic cellsMILTENYI BIOTEC BV & CO KG·Filed 2021·Granted Aug 23, 2022·5 cites·6 claims
- 0395US11033619B2Combination of immune effector cells specific for a target antigen and hematopoietic cells that express the target antigen in an altered formMILTENYI BIOTEC GMBH·Filed 2018·Granted Jun 15, 2021·15 cites·11 claims
- 0494US11883494B2Combination of immune effector cells specific for a target antigen and hematopoietic calls that express the target antigen in an altered formMILTENYI BIOTEC BV & CO KG·Filed 2023·Granted Jan 30, 2024·2 cites·11 claims
- 0593US12246065B2Immunotherapy of cancer patients using CAR T or CAR NK cells combined with hematopoietic cells that have a modified or deleted target antigenMILTENYI BIOTEC BV & CO KG·Filed 2024·Granted Mar 11, 2025·1 cites·26 claims
- 0693US10201606B2Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseasesMILTENYI BIOTEC GMBH·Filed 2015·Granted Feb 12, 2019·18 cites·12 claims
- 0788US12318446B2Reducing side effects of immunotherapy using genetically modified hematopoietic cellsMILTENYI BIOTEC BV & CO KG·Filed 2024·Granted Jun 3, 2025·0 cites·19 claims
- 0884US11890300B2Immune cells expressing an antigen binding receptor and a chimeric costimulatory receptorMILTENYI BIOTEC GMBH·Filed 2017·Granted Feb 6, 2024·3 cites·10 claims
- 0968US2024122976A1Immune cells expressing an antigen binding receptor and a chimeric costimulatory receptorMILTNEYI BIOTEC B V & CO KG·Filed 2023·Application pending·0 cites
- 1060US2025235477A1Method for targeted gene insertion into immune cellsMILTENYI BIOTEC BV & CO KG·Filed 2022·Application pending·0 cites
- 1158US2025255959A1A system for drug-inducible expression of a polynucleotideMILTENYI BIOTEC BV & CO KG·Filed 2023·Application pending·0 cites
- 1250US2022133791A1A Combination of compositions for elimination and enhanced engraftment of hematopoietic stem cells in the bone marrow of a subjectMILTENYI BIOTEC BV & CO KG·Filed 2020·Application pending·0 cites
- 1350US2022220504A1Method for Generation of Genetically Modified T CellsMILTENYI BIOTEC BV & CO KG·Filed 2020·Application pending·0 cites
- 1448US2023313206A1System for inducible expression of an adapter in immune cellsMILTENYI BIOTEC BV & CO KG·Filed 2021·Application pending·0 cites
- 1547US12018273B2CD62L specific lentiviral vector particle for targeted transduction of T cell subsetsMILTENYI BIOTEC BV & CO KG·Filed 2021·Granted Jun 25, 2024·0 cites·14 claims
- 1645US12178872B2Regulatory T cell expressing a chimeric antigen receptorMILTENYI BIOTEC BV & CO KG·Filed 2019·Granted Dec 31, 2024·0 cites·2 claims
- 1745US2021275586A1Use of a car cell having crosslinked disulfide bridge on antigen recognizing moiety for targetting cancer cellsMILTENYI BIOTEC BV & CO KG·Filed 2021·Application pending·0 cites
- 1844US2022315894A1Method for Transduction of T Cells in the Presence of Malignant CellsMILTENYI BIOTEC BV & CO KG·Filed 2020·Application pending·0 cites
- 1943US2023100000A1Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigensMILTENYI BIOTEC BV & CO KG·Filed 2021·Application pending·0 cites
- 2043US2022193137A1Modified immune receptor constructsUMC UTRECHT HOLDING BV·Filed 2020·Application pending·0 cites
- 2142US2004241147A1New isolated dendritic cells, a process for preparing the same and their use in pharmaceutical compositionsFiled 2002·Application pending·0 cites
- 2236US2019315879A1Adapter chimeric antigen receptor expressing cells for targeting of multiple antigensMILTENYI BIOTEC GMBH·Filed 2017·Application pending·0 cites
- 2336US2018112000A1Humanized antibody or fragment thereof specific for cd3MILTENYI BIOTEC GMBH·Filed 2016·Application pending·0 cites
- 2435US12365916B2Adapter-based retroviral vector system for the selective transduction of target cellsMILTENYI BIOTEC BV & CO KG·Filed 2018·Granted Jul 22, 2025·0 cites·26 claims
Join the waitlist — get patent alerts
Get an alert when Andrew Kaiser files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →